Podcasts about Mard

(0:00) Intro(0:12) Aamilon ke paas jana?(3:42) Namaz qaza karna gunah-e-kabeera?(5:07) Jannat kaise milegi? Tafseel se jawab(7:36) Char shadiyon par ayyashi ka taana + parallel nikah(17:16) Rabi Peerzada se shadi ki sifarish karne wala?(19:54) Khawateen ka Mufti sb ka shukriya(22:02) Ayyashi ka taana dene walon ko jawaab(23:40) Hazrat Musa AS ne 10 saal bakriyan kyun charaayeen?(25:00) Nabi ﷺ ki ghurbat mein 9 azwaj — nikah mein barakat(26:15) Nikah aur khushbu — sunnat(27:49) Azwaj e Mutaharat ki qurbani jab talaq ka ikhtiyar diya gaya(28:59) Hazrat Ayesha RA ke alfaaz(29:49) Nikah ke faiday(31:19) Ulama mein achhay kamon ki list?(33:35) Mard ko "he" honay ka ehsas 4 guna zyada kab?(39:37) Jab Mufti sb ne doosri shadi ki?(41:12) Side ki maang?(41:19) Isha 17 rakaat hoti hai, to vitir kaise aakhri namaz?(45:16) Galat taraf gaari chalana?(46:51) Sadqa kisko dena chahiye?(47:05) 19 saal ki age mein shadi?(49:36) Worker ki aisi baat — gheebat hai?(50:24) Jamaat mein kandhay se kandha milana lazmi hai?(51:26) Pants pehnna?(51:48) Makhloot mahal aur prda ki baat karne par tang nazri ka taana?(55:57) Air hostess ke sath Mufti sb ki selfie — wazaahat(1:04:30) Jab aik khatoon Mufti sb ke ghar gayi?(1:05:57) Nabi ﷺ ka waqia(1:06:34) Zamane ke hisaab se tabligh ka style Hosted on Acast. See acast.com/privacy for more information.

Para No. 3 – Surah Al-Baqarah, Ruku #39, Ayat #282-283(0:00) Intro(0:32) Ruku 39, Surah Al-Baqarah, Lafzi Tarjuma(21:04) “Dain” Ke Mamlat / Doosray Ka Maal Nahaqq Khana(24:21) Udhar Ki Iqsam(26:33) Mamlat Likhne Ki Targheeb?(27:09) Writer Ka Adal Ke Sath Likhna(27:55) Writer Ki Payment Ka Zimmadar(30:15) Selected Words Mein Likhne Ka Hunar(35:33) Writing Par Gawah = 1 Mard ya 2 Auratein(37:08) 02 Women's Mind = 01 Men's Mind (Due to Forgetfulness Disorder in Women)(38:18) Likhne Ke Gawah Ka Inkar Aur Mamlat Likhne Mein Jaldi Karna(40:50) Hazir Tijarat Ki Iqsam(41:15) Dua Hosted on Acast. See acast.com/privacy for more information.

(0:00) Intro(1:06) Ehsan Faramoshi — Sabse Bura Aib(2:14) Mufti Sahab ke Purane Dost ka Zikr(3:07) Ehsan Faramosh logon par gussa kyun aata hai?(4:09) Allah ke Behsab Ehsanaat(4:50) Aasaan Ehsaanmandi kya hoti hai?(5:48) Mushkil Ehsaanmandi — Asliyat kya hai?(6:29) Kafir ki Ehsan Faramoshi — (Allah aur waldain ke huqooq na maanna)(6:29) MTM's Advice for West-Influenced Youth(11:04) Muslim vs Kafir in Shukar Guzari — Kaun behtar?(12:40) Allah ka Matloob Shukar — Kya Allah bhi Shukar chahta hai?(13:12) Friends vs Relatives — Ravayya aur haqeeqat(14:57) Business ka Asool — Fraud se kaise bacha jaye?(17:34) Khawateen ka paisa khane wale Bhai aur Shohar(18:25) Paison ke mamlaat mein Aik Number banne ka tareeqa(19:26) Women Rights ke Mubham Naare(20:48) Kafir Allah ke huqooq ko kyun nahi maanta?(21:42) Ehsaan ke lehaz se Shukar karna(22:32) In 4 ke huqooq sabse zyada pamaal kiye jaate hain(23:54) Is 1 ka haq sabse zyada ada kiya jaata hai(24:40) Allah ke Ehsanaat — Kitne hain asal mein?(25:08) Insani Aankhon ki Qeemat — Andazah kab hota hai?(28:08) Kafir ki Na-Shukri ki misaal(31:29) Allah ki Qudrat ke Kamalaat — 5 Sensors aur Honth ka Nizaam(34:27) Amazing Male-Female Pairing System — Fitrat ka tajziya(37:17) Qur'an vs Scientific Theories — Titli, Phool, Deemak, Cheentiyan, Machhar(41:12) Aik Doctor ki “So-Called” Research on Brain(42:17) Islam vs Nazriya-e-Irtiqa(44:04) So-Called Evolution Theories ka postmortem(46:01) Kaainaat ka wajood kaise aaya?(47:28) Aulad: Chehre ki roshan rozaan(48:37) Child Schema — Bachon ke chehre par attract karne wali lines(49:52) Sabse Bari Na-Shukri — Har ni'mat ko sirf nature kehna(51:35) Guthli se aam banna — Allah ki qudrat ka nizaam(53:31) Doodh aur Ghee — Qeemti ni'matain jo bhool jaate hain(54:17) Scientists about Evolution — Kya wo confuse hain?(55:13) Musalman ki Shukar Guzari(55:46) Kafir ki Na-Shukri(57:22) Ilm vs Aqal — Kya farq hai?(1:00:46) Atheist University Professor ka Taleemi Andaz(1:02:40) Creation without Creator? — Aqlmandi ya ghaflat?(1:04:35) Mufti Sahab ka Sawal Aik Atheist se(1:06:08) Allah ke Wajood ke Daleel — Naak, kaan ka mechanism(1:08:35) Mufti Taqi Usmani ka Waqia — Africa mein phoolon ki analysis(1:09:24) Nanhiyal, Dadhiyal, Susral — Risthon se milti izzat(1:11:31) Ghar Damad banne ka masla(1:12:13) Allah ke Ehsanaat(1:12:56) Bani Israel ki Na-Shukri(1:13:47) Chaman/Quetta mein Mufti Sahab ka tajurba — Bina namak ke khana(1:14:50) Allah ki ni'maton ka shukar ada karne ka tareeqa(1:15:46) Mufti Rasheed Ahmed DB ka Isteghna(1:16:33) Museebat mein Shukar Guzari — Kaise mumkin hai?(1:17:12) Waqia: 8 Saal ki beti ki maut (Eid ke doosre din) — Sabir Baap(1:19:29) Waqia: Bachay ki Maut par Na-Shukra Baap(1:20:34) Allah ka Haq ada karne wale kaam(1:21:38) Kanjoosi ka Aadi(1:23:36) Janwaron par Zulm(1:24:44) Mard ke liye Darhi rakhna(1:26:28) Aurat ke liye Parda karna(1:27:01) Dating(1:27:46) Khulasa Bayan + Dua Hosted on Acast. See acast.com/privacy for more information.

Join us for a fun and entertaining episode as Jennifer Emard, the talented singer-songwriter blending modern country with pop, takes on 20 Crazy Questions!

Video Version Only on HCPLive!  In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new key updates on cotntinous glucose monitoring (CGM) systems for diabetes, incuding the Dexcom G7, Libre App, and Medtronic Simplera Sync. Dexcom G7 15 Day CGM On April 10, 2025, the FDA granted clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for individuals aged 18 years and older with diabetes. The G7 CGM now boasts the longest-lasting CGM system with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference (MARD) of 8.0%. Isaacs and Bellini discussed the sensor life of the G7 CGM, with Dexcom announcing only 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. Abbott Libre App With the launch of the new Libre app, Abbott is replacing the Libre 2 and 3 apps with a new all-in-one app that works with all Libre sensors. With the upcoming discontinuation of Libre 2 and 3 (non-Plus) sensors in the US by September 2025, intermittent scanning will be phased out, improving data continuity and aligning with American Diabetes Association (ADA) recommendations. They also highlight Libre's new integration with Glooko, allowing direct data syncing via Bluetooth from the app. This streamlines clinical workflows, supports EHR integration, and includes features like voice-activated carb logging, reducing both patient and provider burden. Medtronic Simplera Sync On April 18, 2025, the FDA approved Medtronic's Simplera Sync sensor for use with its MiniMed 780G insulin delivery system, expanding CGM options for users. The new all-in-one, fingerstick-free sensor offers simplified insertion and enhanced user flexibility while maintaining compatibility with the system's Meal Detection™ technology and adaptive insulin algorithm. A limited US launch is planned for fall 2025. Isaacs and Bellini noted this long-awaited update could improve access and uptake in the US., especially for newly diagnosed patients, thanks to easier usability and compatibility with Medtronic's strong insulin delivery algorithm. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:30 Dexcom G7 15-Day Sensor Approval 00:02:11 Challenges with Sensor Lifespan 00:06:00 Education and Replacement Process 00:09:27 Accuracy and FDA Approval Details 00:11:37 Libre's New Mobile App 00:16:55 Integration with Gluco 00:19:41 Medtronic's Simplera Sync Approval 00:23:03 Future Collaborations and Algorithms 00:28:05 Final Thoughts and Wrap-Up

Welcome to Crazy Women Country, where we shine a spotlight on the incredible women making waves in country music!

Ghair Muslimon ke sawalat, karamaton ka logic, Nabi ﷺ ki sunnat, aur aaj ke muashray ke masail – sab kuch ek jaga. Har jawaz ko daleel aur har shak ko yaqeen mein badalte hue Mufti Tariq Masood sahab ka naya andaz. (0:00) Intro(0:11) Khutba(0:56) Qur'ani Aayaat + Dua(1:48) Non-Muslims ka sawal: “Agar Islam sabse achha deen hai to Allah ne humein ghair Muslim kyun banaya?”(4:42) Mufti sb ka aik Esaai ko jawab(5:42) Ghair Muslimo ki ghalat fehmi ka jawab(7:31) Inheritance vs culture ka clash(9:44) Bazurgon ke silsilon ka ruhani faiz(11:20) Nabi ﷺ ka farman(11:30) Joke on biwi(12:38) Bazurgon ke malfoozat – qeemti moti(13:45) Allah ke nek bandon par karamat ka zahoor(15:56) Malka-e-Saba ka takht – palak jhapakne se pehle!(18:10) Karamat aur atheist mindset ka jawab(19:53) Ghalat zehno ko karamat ka samajhdar jawab(22:26) Takht laane ki karamat – do sawalon ka jawab(23:25) Fazail-e-Aamaal ki karamaton par aitraaz ka jawab(24:42) Allah nek logon ke haathon karamat kyun zahir karta hai?(25:37) Molana Zakariyya ra ke walid ki karamat(25:55) Aik buzurg par zina ki jhooti tohmat ka waqia(28:40) Karamat ke liye do aham cheezein + Mufti sb ke walid ka dekha hua waqia(31:48) Anwar ur Rasheed mein likhi karamat(32:35) India mein 30 saal pehle ki karamat(34:00) Androon Sindh mein karamat ka waqia(34:52) Namaz-e-Istisqa aur dadi sahiba ka suna hua waqia(43:19) Aik doctor ke walid ka aankhon dekha waqia(44:37) Aaj duaein qabool kyun nahi hotin?(46:59) Hamari tauba ki quality?(47:43) Jab dil karamat ko nahi maanta – aik school teacher ka waqia(51:22) Aurat ki late shadi ke nuqsanat(53:19) Mufti sb ki dada banne ki khwahish(54:30) Australia & Norway mein growth ratio(55:51) Khandaan se ghar ki ronaq(56:26) Namaz-e-Istisqa ke sawalat + dua ka asar(58:42) Izzatdar log – Shuhada(59:24) In 2 logon se Allah ka elaan-e-jang (Sahaba & buzurgon ko bura kehne walay)(1:01:31) Jab Mufti sb ne 23 saal ki umar mein aik Saudi aalim par baat ki(1:03:44) Buzurgon ki gheebat(1:04:25) Bachon ko buzurgon ka adab kaise sikhayein? (Ek beti doosray mulk bhaag gayi)(1:06:06) 90's ke bachpan vs aaj ke rishtay(1:07:40) Mard: ghar ka sarbarah(1:08:26) Nabi ﷺ ka farman(1:08:43) Aaj kal ke waldain ki ghalat tarbiyat(1:10:16) Allah walon se mohabbat – farz hai(1:11:13) Khulasa bayan + dua(1:11:31) Fazail-e-Aamaal ki zaeef karamat?(1:11:53) Usman Ansari ka sher for Mufti sb(1:12:13) iPhone gift after Mufti sb's dua?(1:12:45) Tafseer-e-Maududi par raaye(1:13:53) Girls ka co-education mein parhna(1:17:09) 17 saal ke larke ka masla(1:18:33) Shadi apni pasand ki ya waldain ki?(1:19:36) Israeli products ka boycott?(1:19:43) Peshab ke qatre – fiqhi masla(1:20:34) Talaq ka masla(1:21:25) Marhoom walid se wada nibhana ka tareeqa(1:22:33) Karamat par ek aur sawal(1:25:27) Aik atheist ka sawal – jawab(1:25:37) Different perfumes ke saath namaz?(1:28:13) Shaitaan ki tauba ka sawal – university student(1:30:52) Meezan Bank ke profit ka hukm(1:31:57) Isaal-e-sawab aur sajda-e-tilawat(1:32:33) School teacher ki Muharram par ghalat rehnumai Hosted on Acast. See acast.com/privacy for more information.

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, reflect on major announcements and product updates from the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 annual conference. The conversation opens with insights into Medtronic's new Simplera CGM, emphasizing its single-use, disposable design and fully disposable on-body form factor. The hosts highlight improvements over previous iterations, such as the absence of an inserter and a more streamlined adhesive system. Although accuracy data have yet to be released, Medtronic has initiated a pivotal trial, and expectations are high for competitive MARD performance. They then turn to Tandem Diabetes Care's Tandem Mobi pump, recently launched in the US market. The pump's compact size and phone control interface are praised for improving convenience and discretion. Bellini underscores how Mobi shifts the paradigm for pump wearability, with early feedback from patients indicating high satisfaction. Later, the hosts discuss Beta Bionics' insulin-only iLet Bionic Pancreas system, which has expanded availability in the U.S. They review recent clinical updates and ongoing efforts to integrate real-world user data. The system's unique algorithm, which doesn't require manual carb counting or standard pre-programming, continues to generate interest across clinical settings. Additional topics include anticipated innovation from Lilly's new pump platform, the competitive implications for CGM integration, and an emphasis on patient-centered device design. The episode closes with Isaacs and Bellini reflecting on the rapid evolution of diabetes technology and how practitioners can stay current with emerging tools and evidence-based practices. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: Control-IQ+ technology is cleared by the FDA for use in adults with type 2 diabetes in the United States, as of February 25, 2025. The podcast episode erroneously positioned the indication as forthcoming. On March 18, 2025, Tandem Diabetes Care announced the commercial launch, making Control-IQ+ available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Send us a textIf watching an odd little film is a crime, you're going to have to lock us up! This week watched Mickey 17 starring Robert Pattinson and Naomi Ackie. This film got us thinking, wondering, and questioning. Specific questions include:1) Damn! Why don't we try to fix earth first?2) Was Mark Ruffalo imitating a certain political official?3) Why were the Mard inhabitants so dang cute? AND do we think they could explode human heads with their musical wails?All this and more on this week's episode.

(0:00) Intro(0:11) Pehli Shadi Bewah se karna afzal hai ya Kanwari se?(0:58) Fiqah Hanfi ki sabse Motabar Kitab ka Naam?(2:07) Behishti Zevar ke Msaail par Hadis Reference mangne walon ko Jawab(3:29) Masla: Talaq e Salaas(4:12) Mufti sb ke Tafseer Lectures Surah Baqarah mein Talaq e Salaas ka Jawab(4:50) Talaq e Salaas ka Dafan Masla dobara kaise Zinda hua?(5:33) Ehl e Hadison se Sawal(7:19) Mard aur Aurat ki Farq Namaz par Aetraz ka Jawab(8:01) Molviyon ka Zarf(17:39) Behishti Zevar ke Msaail par Aetraz ka Jawab(18:53) National Saving ke Paison ka Hukam?(19:35) Dadi ke diye huay Zevar par Zakaat?(20:44) 10 Moharram ke Rozy par Mufti sb ka Jawab(31:06) Darrhi Barrhanay ki Illat?(35:07) YouTube Earnings?(38:30) Mobile Qiston par lekar Karobar karna?(38:58) Bahu par Saas ki Khidmat Lazim hai. Explanation(42:41) Forex Trading aur Drop Shipping ke Ehkam?(46:15) Gold devalue hone se pehle Zakaat nikalna?(48:52) Fitna Ghamdi “Islam mein Taraweeh Nahi” ko Jawab (Taraweeh 20 Rakaat Dalaail)(58:14) Taraweeh ka Naam Taraweeh kaise para?(1:00:26) Taraweeh: Ramazan ki Raunaq(1:01:10) Taraweeh aur Tahajjud ki Fazilat mein Farq?(1:04:12) Be Lagam Oont: Aajkal ke Scholars(1:07:53) Dr. Israr ki Fazilat par Mufti sb ka Bayan aur Negative Comments(1:10:57) Machini Zabeeha ke Ehkam?(1:17:01) Bahir Mulkon mein Nafarman Bachay/Bivi aur

(0:00) Intro(0:11) Pakistan mein second marriage karna bura kyun?(1:05) Allah ka qanoon vs insaan ka qanoon(3:54) Ramazan taraweeh se pehle Mufti Sahab ki behes Jamiatur Rasheed mein(5:20) Saudia/Yemen/Sudan vs

(0:00) Intro(0:11) Listen to must-hear Tafseer lectures of Mufti Sahab on this channel.(0:48) Yarqan (jaundice) kin cheezon se phailta hai?(1:57) Anbia ke saath Jannat mein rehne wale?(3:19) Muharram mein haleem Pakistani rasam/tafreeh ki niyyat se banana?(5:25) Jamaat ki namaz bila uzar chhodna?(6:25) Family ke saath ludo khelna?(7:03) Jamaat ke peeche Sanaa parhna?(7:07) Munh se “Taa” nikalne ka wazifa?(7:42) Brailvi se shadi karna?(8:12) Muslim aur ghair Muslim ki hadood?(13:44) Mufti Sahab ke walid Sahab ki personality(15:43) Tauheed aur ghair tauheed mein farq ka masla?(17:45) TV dekhna kufr? Ek molvi sb ka fatwa(18:22) Kufr ke fatwon mein ta'weel ki hadd?(21:54) Mufti Tariq Masood Sahab ne Brailvi ulama ke haqq mein awaaz uthai(29:33) PakAid Welfare Trust?(30:59) Mard ke liye silver chain pehenna? + Makrooh aur halal ka farq?(33:23) Mufti sb ke clips ko ghalat rukh dene wale?(35:56) Madaaris mein aqraba parwari ka hal?(41:51) Juma ke khutba ke adab?(42:27) Esai qasai ko samjhana?(45:31) Tableegh mein nikalne ki sharaait?(45:57) Khandani khawateen?(46:44) Masjid-e-Nabvi ﷺ mein namaz?(47:06) Hazrat Abu Bakr (RA) ko Siddiq na maanna kufr?(47:48) Maa ki ghalti par kaise tokain?(50:41) Witr 3 rakaat ke dalaail?(52:57) Zakaat vs Qurbani?(53:35) Nikah ke 6 kalme?(54:07) Turkey mein bida'at?(54:31) Mtm's experience of the first Taraweeh in Turkey?(58:18) Turkey mein ek aur bida'at Hosted on Acast. See acast.com/privacy for more information.

durée : 00:46:53 - On n'arrête pas l'éco - par : Emmanuel Duteil, Valentin Pérez - Au menu ce samedi : débat sur la planète éco en France et dans le monde en 2025, détour par les USA, question boulot et zoom sur les transports routiers avec un reportage sur les routes décarbonées et un entretien avec le DG de la Sanef. Quelles perspectives pour les autoroutes françaises ? - réalisé par : Céline ILLA, Helene Bizieau, Etienne BERTIN

(0:00) Intro(0:17) Precious recipe in the end(1:08) Mard auraton pr hakim?(2:02) Allah zameen aasman ka noor hai(2:54) Nabi ﷺ ki tahajjud mn duaDebunking Misconceptions(5:12) Lafz Ro'oya pr Ghamdi ka ghalat ki tehreef(7:08) Hayat-e-Esa as pr Ghamdi k ghalat aqaaid(9:50) Hazrat Esa as k bary mn Musalmano aur Esaiyon ka same concept(12:38) Meraj k waqia k dalaail (lafz Ro'oya, Hazrat Yusuf as ka khaab)(13:56) Lafz Ro'oya aur Surah Bani Israel ki aayat(15:15) Zaqqoom ka darakht aur dozakh ki aag mn darakht ka paida hona (aazmaish)Tahajjud and Prayer Insights(17:07) Hazrat Abdullah Bin Umar ra ny is khaab k baad sari zindagi tahajjud parhhi?(19:24) Nabi ﷺ ka mamool tahajjud aur Fajar ki sunnaton k darmiyan. Lamby sajdy Sunnat. Hazrat Ayesha ra k razaai bhanjay ka zikr.(22:26) Pakistan mn Fajar k baad sonaSurahs and Prophetic Practices(23:21) Surah Wazzuha ki aayaat ka nazool(24:45) Tariq: Raat ko aany wala sitara(25:52) Hazrat Ali sari zindagi tahajjud guzar bany jb Nabi ﷺ unky ghar aayay aur soty daikha(29:13) “Nabi ﷺ ny Ishraaq ki namaz kabhi nhi parhhi” Hadis pr Hazrat Ayesha ra ka ruju. (Farz ho jany k dar se musalsal amal nhi kiya)(31:31) Lafz Ro'oya ka itlaqPrecious Recipe for Health(32:11) Bareek naujawanon k liye ba kamal, be misal recipe(33:14) Ingredients:•Maghaz Badam (meetha) Qandhari ya Irani: 01 pao•Maghaz Kaddu: 01 pao•Maghaz Kharbooza: 01 pao•Maghaz Tarbooz: 01 pao•Khash'Khaash: 01 pao•Dry coconut (sookha narial): 01 pao(34:24) Making:Char maghaz dho kar (badam without peel) thorry se desi ghee (cow) main light roast karain. Add crushed khashkhash and mix with crushed coconut. Avoid water or moisture. Make a paste using pure honey or gur ka sheera. Add remaining desi ghee, cool it, and store in an airtight glass container.(43:57) How to take:Take 1 spoonful on an empty stomach, chew well, and drink a glass of warm milk.(47:31) Benefits:•Bright face and sharp eyes.•Improved health within two months. Suitable for women too.(48:31) Mufti sb ka 20/25 saal pehly aazmaya hua balanced diet nuskhaReligious Practices and Fiqh(49:27) Tayammum k bary mn ahadis(58:14) Napaki ki halat mn Qur'an, namaz parrhny k ehkam(1:01:04) Napak zameen ko pak krna(1:10:10) Deen k daai ki zimmadari: Narmi se pegham pohnchana Hosted on Acast. See acast.com/privacy for more information.

(0:00) Intro(0:12) Aamilon k pas jana?(3:42) Namaz qaza karna gunah e kabeera?(5:07) Jannat mein jana kaise mumkin hai? Tafseeli wazahat karein?(7:36) Char shadiyon par aiyyashi ka ta'ana aur nikah in parallel(17:16) Rabi Peer Zada se shadi ki safarish krny wala?(19:54) Auraton ka Mufti sb se shukriya(22:02) Aiyyashi ka ta'ana deny walon ko jawab(23:40) Hazrat Musa as ne 10 saal bakriyan kyun churaai?(25:00) Nabi ﷺ ki ghurbat mein 9 azwaj: Nikah mein barkat ki alamat(26:15) Nikah aur khushbu: Sunnat(27:49) Azwaj e Mutaharat ki qurbani ki jazaa (jab Nabi ﷺ ne talaq ka ikhtiyar diya)(28:59) Hazrat Ayesha ra ke alfaaz(29:49) Nikah ke faiday(31:19) Ulama mein achay kaamon ki list?(33:35) Mard ko “he” hone ka ehsaas 04 guna ziada kab?(39:37) Jab Mufti sb ne doosri shadi ki?(41:12) Side ki maang?(41:19) Esha 17 rakaat to aakhri namaz witr kaisi?(45:16) Ghalat raah jana kaisa hai?(46:51) Sadqa kisko dein?(47:05) 19 age mein shadi?(49:36) Worker ki aisi baat gheebat hai?(50:24) Jamaat mein kandhe se kandha milna laazmi hai, jab brabar wala side pr ho?(51:26) Pants pehna?(51:48) Makhloot mahol aur parda ki baat krny par tang nazri ka ta'ana?(55:57) Mufti Sahab ki air hostess k sath selfie ki wazahat?(1:04:30) Jab aik khatoon Mufti sb ke ghar gye?(1:05:57) Nabi ﷺ ka waqia(1:06:34) Zamany ke hisab se tabligh ka styleCredit for the timestamps goes to @mrs.masroor8476 Hosted on Acast. See acast.com/privacy for more information.

Gonzaga's woes in Climate Pledge Arena continue with an inexplicable loss to Mark Pope's Kentucky team. We'll attempt to explain it. Then we'll look ahead to what has quickly become a monstrously important meeting with the Huskies in the Garden. Mard is not optimist.  The boys then close out with some memorable free agent signings in honor of Chris's Mets signing Mr. Soto. patreon.com/freeirabrown 

Avec : Arnaud Quémard, directeur général de la Sanef. - Tous les matins à 7h40, l'invité qui fait l'actualité. Un acteur incontournable, un expert renseigné... 10 minutes d'interview sans concession avec Apolline de Malherbe et les témoignages des auditeurs de RMC au 3216.

Chris, Adam and Mard react to a disappointing showing by Gonzaga in Atlantis. What went wrong against the Mountaineers? We have thoughts. We also shout out a tremendous week in assist to turnover news and look ahead to the duel with our old nemesis Mark Pope, but he's a different cat this time around. The women will look to rebound after a rough week in the Paradise Jam. Support the Show at patreon.com/freeirabrown

The Zag Men and Women take their talents to the tropics, in the Battle For Atlantis and Paradise Jam respectively. What can you expect from the squads? Feasting on opponents? Earning their just desserts? Adam, Chris, Mard, and special guest Steven Karr walk you through the upcoming week. patreon.com/freeirabrown to support the show!

(0:00) Intro(0:17) Ayaat from Surah Ma'arej(0:33) Sabar ka thermometer?(3:10) Jobless hona: Mard ki aazmaish(3:50) Mufti sahab ke bayanat “depression topic” par hi kyun hotay hain?(4:17) 3 topics of Mufti Tariq Masood's bayanat(4:31) Low-level status, jhootay aamil ka Mufti sahab par aitraaz(6:21) Mufti sahab shadi ko society ki zarurat kyun kehte hain?(7:21) Motivation etiquettes?(Qur'an mein namaz aur roza ki baar baar takeed kyun?)(9:01) Roze se weakness?(10:38) 2 namazon ko ikatha karne par engineer ko Mufti sahab ka jawab(17:45) Mufti sahab ka aamilon ko challenge(18:31) Defence, shadi par bayan mein Mufti sahab ne kanwaron ko jooton mein kyun bithaya?(19:38) NADRA mein Mufti sahab ko kya information mili?(20:43) Namaz: Aik mustaqil ibadat(22:04) Tension par zyada bayan?(22:38) Nabi ﷺ ka farmaan(23:07) Dunya ke piche bhagnay walay ka anjam(25:07) Precious tension?(27:25) Mufti sahab ke shaikh ka istighna(28:28) Buzurgon par 2 clips(29:22) Ghurbat mein istighna(30:38) Istighna vs bhikari pan(32:14) Tang dil owners(33:14) Nabi ﷺ ka istighna(Hazrat Umm e Salma ko nikah ka pegham. Bewa ke bachon ko palne mein liberals ko jawab)(35:29) Bachon ke samne, behan bhaiyon se dealing(37:30) Allah ki pasandeeda sifat(38:10) 3 inamat ke mustahiq?(39:03) Nabi ﷺ ka farmaan(39:10) Mimber: Source of income?(40:12) 1995/96 ka waqia(41:28) Masjidon par qabzay(42:12) Ghurbat ka khauf(43:31) Factory owners: depression patients(44:15) Muhammad Afaq ke alfaz, showbiz stars ke bare mein?(45:15) Showbiz stars old age vs deendar ka burhapaa(47:03) 1975 ka hero 2024 mein?(48:04) Izzat, dolat, sehat ko target banane walay(49:08) Gym walay ka waqia(50:36) Aik khwahish, hazar khwahishat ka zariya?(52:23) More and more repetition(53:51) Waqia: Be-sakoon zindagi(55:28) Dunya kisko kitni milti hai?(57:06) Kamyabi ka zariya, nakami mein tabdeel?(58:52) Purani qaumon ki tension?(Mazboot zati ghar banana)(1:00:30) After 40 age, zati ghar ki tension lena kaisa hai?(1:02:09) Rent par rehne walon ko Mufti sahab ki naseehat(1:05:44) Nabi ﷺ ka farmaan(1:06:08) Mufti sahab apna zati ghar kyun nahi banate? (10 saal pehle aik shakhs ka sawal)(1:08:01) Tension ka ilaj?(1:09:03) Dua Hosted on Acast. See acast.com/privacy for more information.

What was it like driving home on the 10 after that USC "loss?" Well it was smooth sailing, kids, because that's an exhibition. Next on the GU calendar is decidedly NOT an exhibition as the Baylor Bears and Scott Drew make the trip to Spokane. Are you scared? Mard isn't.  We'll take a walk through the schedule, discuss our expectations and identify our favorite match-ups for the men and the women.  Support the show at patreon.com/freeirabrown

You're going to get a lot of player preview talk on this pod. But not just from Adam, Chris and Mard, we welcome, from the House of Krause, Tuck Clarry! We're deep diving into this roster to discuss expectations, roles and jumps.  But that's not all, the women's team is facing a massive transition this season with the loss of several senior leaders.  Lastly, we'll discuss the exhibition coming up against the Trojans in the desert.

This week's episode of The Football Letter podcast features two standout volunteer leaders. Alumni Council member and President of the African American Alumni Organization (AAAO) of Washington, D.C., Jeremy O'Mard '13 Behrend, talks about the mission our AAAOs, previews this weekend's Black Alumni Reunion, and discusses the importance of representation at Penn State. We also chat with Madison Chapter President, Phillip Bower '99, 01 M.S., about how the chapter plans to welcome Penn Staters to Madison this weekend for Penn State football's matchup with the Badgers, how the Madison chapter unites area Nittany Lion alumni and fans on game day, and how it connects Penn Staters year round.-------------------------------------------------------------------------------------------------------------------- Learn more about our African American Alumni Organizations Connect with the Madison Chapter:WebsiteFacebook GroupInstagramLearn more about the Penn State Alumni Association: alumni.psu.edu. Follow the Penn State Alumni Association on:FacebookX (Twitter)InstagramLinkedIn

JF criminel rapidement approché par les motards il devient un incontournable du crimes organisé au Québec. Entre la prison, la jalousie et la compétition il à été victime de plusieurs tentatives de meurtre. Il a quitté le milieux dégoûté par ce qu'il devenait. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Kraziness in the Kennel is in the rear view mirror. The season is nigh and we are high on this squad. We'll go through some takeways from both Men's and Women's Krazines. Oh, and Mard's vocal stylings return for season 11! Support the show! Patreon.com/freeirabrown   Chapters 07:59 Craziness in the Kennel: Event Highlights 15:59 Player Insights and Season Expectations 19:33 Physical Transformations and Player Development 22:03 Scrimmage Highlights and Player Performances 26:00 Evaluating New Additions and Returning Players 28:57 Coaching Insights and Team Dynamics 35:55 Women's Team Updates and Future Prospects 41:11 Impatience and Performance at FanFest 44:06 Roster Changes and New Faces 45:40 Looking Forward to the Season 51:39 Key Players to Watch 56:30 Depth and Team Dynamics 01:02:50 Closing Thoughts and Future Expectations

After several episodes of will they? won't they? Gonzaga and the PAC 12 finally hook up after the PAC 12 FINALLY broke up with their loser boyfriend. It's not cheating if you're on a break. What was I writing about? In this episode, Adam, Chris and Mard discuss Gonzaga's impending move to the Pac-12, exploring the implications for the basketball program, fan engagement, and the overall landscape of college sports. The conversation highlights the excitement surrounding the upcoming basketball season and the changes that come with it, emphasizing the importance of adapting to the evolving world of collegiate athletics. Chapters 00:00 Gonzaga's Move to the Pac-12: A New Era Begins 03:00 Reactions to Conference Realignment: Mixed Feelings 05:58 The Impact on Gonzaga Basketball: A Competitive Edge 09:06 Rivalries and New Dynamics in the Pac-12 11:56 Future of Gonzaga: Opportunities and Challenges 14:55 The Broader Landscape of College Sports 17:54 Fan Engagement and Game Atmosphere: A Revitalization 20:59 Financial Implications: A Boost for Gonzaga 23:55 Looking Ahead: The Future of Gonzaga Athletics 27:01 Final Thoughts: Embracing Change and New Beginnings We'd love for you to support the show at Patreon.com/FreeIraBrown! Thanks!

Speaking with Aaron Rand is Dimitri Soudas, former Director of Communications for Harper and political commentator. 

Presenting the next song from Naatak's VRINDAVAN, our 110th production. In Ranaji Mharo Mard Maryo, presented as a Meera bhajan, we hear the widows talking about only wanting to live in Vrindavan and devote themselves to Krishna now that they've lost their husband.About the PlayIn 2014, Bollywood's dream girl Hema Malini became Member of Parliament from Mathura. When visiting a widow-home in Vrindavan, she suggested that Vrindavan widows should remain in Bengal instead of coming to over-crowded Vrindavan. The uproar that followed involved many actors – NGOs, the BJP, Bengal Chief Minister Mamata Banerjee, and Hema Malini.This incident provides the inspiration for Vrindavan, City of Widows, in which 12 feisty widows live in raucous celebration until a Bollywood actress arrives to disrupt their lives. Vrindavan is a grand musical, juxtaposing the colorful love of Radha and Krishna with the stark existence of Vrindavan widows, and told through humor and wit, the songs of Meera Bai and the gyrations of Bollywood songs. The play features spectacular sets, costumes and lights, along with live music by Nachiketa Yakkundi and his team.A news item on the incident that became the genesis of this play: http://www.ndtv.com/india-news/widows-from-bengal-bihar-stay-there-why-crowd-vrindavan-hema-malini-667204Support the Show.Support the Show.Subscribe to Naatak Radio on Apple Podcasts, Google Podcasts, Spotify, Jio Saavn or wherever you get your podcasts. You can also listen to our library of over 100 episodes on our website at naatak.org/naatakradio/Love the show? Consider supporting the show here.

MARD (Mean Absolute Relative Difference) is often linked to continuous glucose monitor accuracy, but did you know there's no universal standard for how companies measure it? In this episode, Tim Street from Diabettech dives into the lack of regulation in CGM clinical trials, revealing how manufacturers might manipulate MARD to appear more accurate.   T1D Exchange Registry Sign up  (US only)   Join our Newsletter | Diabetech Community Discord   Support Diabetech on Patreon   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook   Follow Tim's Blog: Welcome to the Wild, Wild West: the CGM head-to-head study   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with a physician before making changes to your health care. 

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study looks at insulin needs in men vs women, updates on stem cell transplants and a new look at COVID 19 and T1D plus a fully implantable CGM is announced. We'll also tell you about a T1D athlete drafted to the MLB. Lots more in this week's episode, full transcipt below.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Do men and women have different insulin requirements? A new study conducted across Europe says yes – women overall need less. Published in the Journal of Diabetes Science and Technology this looked at over 9,000 adults with type 1 diabetes using data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop pump system. In this study, women needed 14-percent less insulin overall than men. These researchers say these findings have important implications for the practical management of insulin therapy and highlight the necessity of considering gender as a crucial factor in diabetes treatment. The treatment guidelines provided by American and European Diabetes Societies do not currently have gender-specific recommendations for insulin-weight ratios. The co-founder and Chief Scientific and Technical Officer for Diabeloop. “This study also highlights the capacity to discover new insights from big-data analysis of real-world data.” *Insulin Requirements According to Gender and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery, https://doi.org/10.1177/19322968241252366). https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/27419187/diabeloop-study-reveals-significative-gender-differences-in-insulin-requirements-for-type-1-diabetes-patients/   XX New drug therapy in those lucky diabetic mice boosted insulin-producing cells by 700% over three months, effectively reversing the disease. Scientists at Mount Sinai and City of Hope have been able to grow new beta cells in the body, in a matter of months. The therapy involved a combination of two drugs: one is harmine, a natural molecule found in certain plants, which works to inhibit an enzyme called DYRK1A found in beta cells. The second is a GLP1 receptor agonist. The latter is a class of diabetes drug that includes Ozempic, The researchers tested the therapy in mouse models of type 1 and 2 diabetes.. The signs of the disease quickly reversed, and stayed that way even a month after stopping the treatment.   The results are intriguing, but of course being an animal study means there's still much more work to be done before it could find clinical use. So far, harmine alone has recently undergone a phase 1 clinical trial in humans to test its safety and tolerability, while other DYRK1A inhibitors are planned for trials in humans next year. https://newatlas.com/medical/diabetes-reversing-drug-boosts-insulin-producing-cells/ XX Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. New info from Vertex shows that of a total 17 patients who received a full dose of their  investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880), three, thus far, have achieved the primary study efficacy endpoint of elimination of severe hypoglycemic episodes with A1c < 7% at 1 year and the secondary endpoint of insulin independence. Others are on the same trajectory, Piotr Witkowski, MD, PhD, professor of surgery at The University of Chicago, Chicago, said at the recent American Diabetes Association (ADA) 84th Scientific Sessions. In his presentation, Witkowski also provided details about the deaths of two study participants that the company had announced in January 2024, neither of which were related to the VX-880 product. In fact, there have been no severe adverse events related to the product itself, with most due to either the infusion procedure or the immunosuppression. "These data highlight the curative potential of VX-880 in people living with type 1 diabetes and support further evaluation of VX-880 toward pivotal development," Witkowski said. For now, patients selected for the study are those who experience frequent severe hypoglycemia deemed to be a greater risk to the patient than that of immunosuppression. However, Ahn pointed out, "With VX-880, the obvious fly in the ointment is the need for immunosuppression which carries significant risk…There are multiple solutions being proposed, but we are still waiting for data as promising as the initial Vertex data is on that front." https://www.medscape.com/viewarticle/stem-cell-derived-islets-continue-show-benefit-t1d-2024a1000cx1 XX Still lots of COVID studies coming in about type 1. A German study suggests COVID 19 may speed up progression of existing but presymptomatic T1D in kids. These researchers had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years. They noticed an increase in the numbers of Incidence of clinical type 1 diabetes nearly doubled after the pandemic started. "We know that the virus can infect the pancreatic islets so it could be causing damage or change in the beta cells that make insulin," said Ziegler when discussing possible mechanisms behind this association. "Second, there is generalized inflammation during the infection and there may be a stimulation of the immune response. Third, there could be metabolic stress from the infection that affects the beta cells that make insulin. To dive into this topic, youth were identified in the German Fr1da-screening program from 2015 to 2023. All patients had presymptomatic diabetes defined as persistent, confirmed positive results for two or more islet autoantibodies. Their progression was monitored at 3- to 6-month intervals. Clinical type 1 diabetes was defined according to American Diabetes Association   COVID infection was either self-reported via the family or identified with SARS-CoV-2 antibodies were confirmed in blood samples collected at study visits.   Vaccination against COVID-19 may be one way to protect presymptomatic type 1 diabetes youth from progression, Ziegler added. She said her group is currently testing whether COVID-19 vaccination can reduce new-onset, presymptomatic type 1 diabetes in a clinical trial  of children with genetic risk factors for the condition. https://www.medpagetoday.com/endocrinology/type1diabetes/111084 XX The FDA says no – for now - to Novo Nordisk's weekly insulin.  This has been approved in Canada and should be available there shortly. But the FDA says it wants more information related to the manufacturing process and the type 1 diabetes indication to complete the review. Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps. The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-novo-nordisks-weekly-insulin-2024-07-10/ XX A couple of weeks ago we spoke to the attorneys taking on CGM monitronig in schools. They've helped a family in Connecticut and set a precdent.  A child with autism and diabetes was not getting reasonable accommodations under the federal Americans with Disabilities Act in a public preschool program. I'll link up the press release from the DOJ but this family wasn't getting any support and it just wasn't safe. The lawyers here tell me the ruling and settlement is just going to help them going forward as they try to make schools complient with CGM as a reasonable  accomodatin. https://www.justice.gov/usao-ct/pr/aba-therapy-provider-make-changes-comply-americans-disabilities-act   XX Ozempic could lower the risk of dementia and a range of other mental problems compared with other existing treatments for patients with diabetes. What's more, researchers found that Ozempic cut nicotine dependence in those patients.   This study relied on medical records from more than 100,000 U.S. diabetes patients, including more than 20,000 who were prescribed semaglutide between December 2017 and May 2021. After a year, patients who took Ozempic had a 48% lower risk of developing dementia than those on Januvia. The risk in Ozempic patients was also 37% lower than those who took Glucotrol and 9% lower than those on Jardiance. Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. But the authors emphasized that the analysis is observational. The results need to be replicated in a controlled trial that assigns patients to randomly take Ozempic and the other drugs, according to Dr. Max Taquet, another Oxford clinical lecturer and senior study author. https://www.cnbc.com/2024/07/16/healthy-returns-ozempic-may-lower-dementia-risk-nicotine-use.html XX   Edgepark Commercial XX The Omnipod 5 with Dexcom G7 integration is now available through select pharmacies with full availability expected in the fall.   The System uses new Pods that are compatible with both Dexcom G6 and G7, but the prescription code will stay the same as the current Omnipod 5 Pods. This means the community will have similar insurance coverage and access to what they have with Omnipod 5 today.   If you're looking to start on Omnipod 5 and you're currently using Dexcom G7, your doctor will need to send a prescription for both the Omnipod 5 Intro Kit and Omnipod 5 Pods, compatible with Dexcom G6-G7, to ASPN Pharmacies.   You can learn more at https://www.omnipod.com/innovation/dexcom-g7.   If you are already using Omnipod 5, you will get the new Pods compatible with Dexcom G6 and G7 through your Pod refills. You do not need a new prescription. The week of July 29th, you will receive a free software update for the Omnipod 5 App to your Controller or compatible Android smartphone which is needed to use the System with Dexcom G7. Accept the update. We recommend you continue to use your current Omnipod 5 Pods and Dexcom G6 supplies until the new Pods compatible with Omnipod 5 with Dexcom G6-G7 are available at your preferred pharmacy.   We'll email our users when the new Pods are available in most pharmacies.   You can learn more at https://www.omnipod.com/innovation/new-compatible-devices   XX Big promises about long-term implantable blood glucose monitor from a company called Focus. They say they're partnering with Glucotrack to quote - transform how people with diabetes interact with their condition. They're not calling this a CGM – rather it's a CBGM, continuous blood glucose monitor because it will measure glucose levels in blood, not in interstital fluid like CGMs do. They company says this is a fully subdermal location, with no external wearable. In preclinical studies, the CBGM has a MARD of 4.7% at day 90. That is MUCH lower than CGMs on the market – Dexcom and Libre are in the low 8s right now. BUT.. it hasn't been fully tested in people yet. Human clinical trials are set to start later this year. https://www.drugdeliverybusiness.com/focus-collaborates-glucotrack-implantable-cbgm/ XX Big congrats to Jamie Ferrer (Chy-may Fer-rare) On Monday, Ferrer's dream was realized when the Twins selected the Florida State outfielder in the fourth round (No. 126 overall) during Day 2 of the MLB Draft. Minnesota vice president of amateur scouting Sean Johnson said the club had its eyes on Ferrer since high school. “Recently, I was in Orlando at a conference called, “Friends for Life with CWD [Children with Diabetes],” and we had an event that was a sports day. … Kids would come up to me and either them or their families would ask me how I dealt with this [or that],” Ferrer said. “And seeing their faces light up whenever I said I was diagnosed at three and I played college baseball. … You hear people tell you no and that you can't do this because you have Type 1 diabetes … So why not inspire as many people as I can?”   “I'm super proud of being a Type 1 athlete, and it's something that I'll never shy away from talking about or showing off my insulin pump because it's who I am and it's something that I've had to deal with my entire life.” https://www.mlb.com/news/jaime-ferrer-selected-no-126-overall-by-twins-in-2024-mlb-draft XX Join us again soon!

I spoke with Know Labs about the KnowU cgm, its non-invasive continuous glucose monitor powered by RF Dielectric Spectroscopy technology. We cover how the tech works, its recent study showing 11.1% MARD accuracy, and the road toward FDA clearance. Do you think non-invasive CGMs are the future?   Join Patreon for Exclusive Content   Fill out T1D Exchange Registry    Watch Video Podcast on Youtube    Follow for more: Instagram | Tik Tok | YouTube | Facebook   Send us Feedback & Join the Newsletter   DISCLAIMER: This podcast is not medical advice. Always consult with your doctor before making changes to your health care. 

Tafseer 04 | Mufti Tariq Masood Speeches

Sunday Bayan 03-03-2024｜Mufti Tariq Masood Speeches

Welcome to another Tired and Tested podcast! In which Sophie recalls her eventful holiday in the sun, involving a long-haul flight with a toddler, an older-child meltdown and a brush with tennis legend Andy Murray. She also visits Urban Dictionary Corner, where she has to work out what a 'flying squirrel' might be! Want to win a FREE ICONIC MASCARA? Submit your parenting tale to tiredandtested@acast.com - and if we pick yours, we'll send you a free mascara!Sophie is on a UK tour! Find out where you can see her hereTickets for Sophie's tour in Australia and New Zealand hereFollow Tired and Tested on Instagram Hosted on Acast. See acast.com/privacy for more information.

Another unworldly performance by Anton Watson is squandered by a 10 percent shooting performance from deep. Gonzaga has no good wins and is looking at the bubble. Mard is not doing well. Is there a light? We'll discuss it this week on Free Ira Brown! THE Gonzaga Hoops Podcast. The Gonzaga Women, on the other hand, are on track for a protected seed in Spokane come March. Mard is doing well, after all. @freebrown

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: an existing drug for arthritis is being studied for treatment of T1D, poison control centers report a big increase in calls about misdosing of Ozmepic and semaglutides, Tandem releases it's Tandem Source software, we've got an update on a possible non invasive glucose monitoring system, ADA releases it's standards of care and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week… XX A world-first clinical trial has found a common drug used to treat rheumatoid arthritis can suppress the progression of type 1 diabetes in recently diagnosed patients. Australian reserachers say they've discovered that baricitinib *bare-uh-sit-en-ub* can preserve the body's own insulin production. The scientists recruited 91 people, aged between 10 and 30 years old, to take part in the double-blind randomised trial. All patients had been diagnosed with type 1 diabetes within the last 100 days and continued with their prescribed insulin therapy throughout the study. The results showed those in the baricitinib group were able safely and effectively to preserve their body's own insulin production and suppress the progression of type 1 diabetes. "Our trial showed that, if started early enough after diagnosis, and while the participants remained on the medication, their production of insulin was maintained. "People with type 1 diabetes in the trial who were given the drug required significantly less insulin for treatment." Dr Faye Riley, research communications manager at Diabetes UK, said of the latest trial: "These findings show by tackling the root of type 1 diabetes - an immune system attack - an existing drug can help to shield the pancreas, in people recently diagnosed with type 1, so they can continue making more insulin for longer. "This can give people with type 1 diabetes much steadier blood sugar levels and help to protect against serious diabetes complications down the line. "Immunotherapies are edging us towards a new era in type 1 diabetes treatment, and could help us overcome a major hurdle en route to finding a cure for the condition. "This trial takes us another step closer." The study was funded by JDRF, a non-profit organization which focuses on type 1 diabetes research. The research has been published in the New England Journal of Medicine. https://news.sky.com/story/world-first-trial-finds-arthritis-drug-may-help-treat-type-1-diabetes-13024706 XX Earlier this month, Dexcom's G7 became compatible with two pump systems: Beta Bionic's ilet pump and Tandem Diabetes tslim X2. Current customers should have received instructions on how to download the updated software – new pumps will be shipped with G7 software already loaded. Tandem has also announced their new Tandem Source platform – full launch in the US with international rollout slated for next year. Anyone in the U.S. who uses a Tandem pump—as well as their respective healthcare providers—will now have access to the Source platform. On the patient side, insulin dosage data will automatically transfer from the pump to the platform, by way of the t:connect mobile app, where it'll be compiled into three reports for your doctor. Patients will also be able to use the platform to access new software updates for their pumps and to reorder supplies as needed. Long term, the company hopes to use the data from users – which would be blinded- to update automated insulin dosing algorithms. https://www.fiercebiotech.com/medtech/tandem-begins-full-us-rollout-source-diabetes-management-platform XX New look at benefits from a plant based diet – this research says it can reduce the risk of type 2 diabetes by 24%. It's not just about weight loss. They reviewed data on more than 113,000 participants in a large-scale British observational study, gathered over 12 years. They found that normal values for cholesterol, blood sugar, inflammation, and insulin are associated with a low risk of diabetes. They also found that good liver and kidney function is important in diabetes prevention. A plant based diet helped with all of those factors. The researchers do point out that there is such a thing as an unhealthy plant-based diet. Those that are still high in sweets, refined grains and sugary drinks are associated with an increased risk of type 2 diabetes, researchers found. https://www.usnews.com/news/health-news/articles/2023-12-13/plant-based-diets-cut-diabetes-risk-by-24 XX Reports of more patients with type 2 diabetes having trouble getting coverage for medication like Ozempic and Mounjaro – because health insurance companies are putting new restrictions in place. Most U.S. health plans cover GLP-1s for type 2 diabetes but many providers will prescribe it off label for weight loss. There is another medication – Wegovy – approved for weight loss, it's the same drug as Ozempic just packaged in a difference dose and name. The average number of weekly Ozempic prescriptions rose 33% between the first and third quarters of this year, but has since dropped more than 6% to about 431,000, according to Iqvia Institute for Data Science. Doctors and patients are bracing for changes in January, when individual health plans often set new coverage terms. "It may be that January 1, all of a sudden something that was covered is no longer," said Dr. Robert Gabbay, chief science officer at the American Diabetes Association. https://www.reuters.com/business/healthcare-pharmaceuticals/us-diabetes-patients-face-delays-insurers-tighten-ozempic-coverage-2023-12-12/ XX Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide, with some people reporting symptoms related to accidental overdoses. From January through November, the America's Poison Centers reports nearly 3,000 calls involving semaglutide, an increase of more than 15-fold since 2019. In 94% of calls, this medication was the only substance reported. The compounded versions of semaglutide are often different from the patented drug. Many contain semaglutide salts called semaglutide sodium and semaglutide acetate. The FDA says the salt forms of the drug have not been tested and approved to be safe and effective the way the patented form of the medication has, and thus they don't qualify for the compounding exemption in the law for drugs in shortage. In other cases, the compounded versions are sold in unapproved dosages. But these compounded versions are popular because they may cost less out-of-pocket, especially if the treatment isn't covered by insurance. The name-brand drugs are sold in pre-filled pens, which come with some safeguards. Patients dial to the correct dose and click to inject, so it's harder to make mistakes. Compounded versions, however, typically come in multidose glass vials, and patients draw their own doses into syringes. It's easy to get confused. https://www.cnn.com/2023/12/13/health/semaglutide-overdoses-wellness/index.html XX XX Type 2 diabetes patients who received endocrinology care through telehealth alone had poor glycemic outcomes compared with those who received in-person or hybrid care, which contrasts with prior research findings, according to a new study. Previous research has shown that telehealth is effective in improving glycemic control, but there has not been enough data on utilization and outcomes linked to routine telehealth care for type 2 diabetes since 2020, especially in the endocrinology setting, the researchers wrote. One reason may be that the strategies to support glycemic improvement deployed during in-person appointments, like self-management education and sharing home blood glucose data, have not been consistently translated to telehealth. “Implementation of approaches to overcome these differences, such as team-based virtual care and technological tools to automate blood glucose data sharing, are needed to ensure all patients receive high-quality diabetes care regardless of care modality,” they wrote. These study findings contrast with previous research, including a study published in early 2022 that revealed that telehealth maintained quality of care and led to better health outcomes for patients with type 2 diabetes during the COVID-19 pandemic. The study included 16,588 with type 2 diabetes who received care before or during the pandemic, with 7,581 having a telehealth visit with either a primary care physician or an endocrinologist. https://mhealthintelligence.com/news/telehealth-only-care-fails-to-improve-type-2-diabetes-outcomes XX Medtronic's deal to buy a South Korea based insulin patch pump maker is off. Back in May Medtrnoic announced a 738-million dollar deal to buy EOFlow, which makes EOPatch, a tubeless, wearable and fully disposable insulin delivery device. EOFlow already launched its EOPatch insulin delivery system in Korea and Europe. The company submitted the insulin delivery device for U.S. FDA clearance in January. https://www.massdevice.com/medtronic-nixes-738m-deal-for-insulin-patch-pump-maker-eoflow/ XX Commercial XX Update on non invasive continuous glucose monitoring. The most recent validation of the technology's accuracy has been released as a preprint. In an experiment, researchers fed thousands of radio frequency glucose readings into a machine learning model to translate them into blood sugar values and compared the results against those from a Dexcom G6. CGM accuracy is judged by mean absolute relative difference, or MARD. The statistic is reported as a percentage: a MARD of 10 percent, for example, means that the CGM is on average within 10 percent of the reference value. The Bio-RFID system scored a MARD of 11.27 percent. In truth, this result is difficult to interpret. Though Bio-RFID's MARD is not yet in the same neighborhood as its competitors' (the Freestyle Libre 3 and the Dexcom G7 report MARDs of 7.9 percent and 8.7 percent, respectively), the experiment wasn't a true test of the device's capabilities, because it didn't use a lab-drawn glucose measurement as its reference value. The volunteers also did not have diabetes, which meant that their blood sugar levels were likely more stable than those of most future customers. The FDA has specific accuracy standards that it expects CGM manufacturers to meet for devices intended for “nonadjunctive” use and for use in a closed-loop insulin pump system. Know Labs's product will need to meet these objective standards to be validated as a truly reliable CGM. The Path to Approval “Our expectation is that we'll be in front of the FDA as we move into the second half of 2024,” says Erickson. Much larger trials will be needed to show that the device works and meets FDA standards. Erickson says, “We expect to have an FDA-cleared device in 2025.” Though the business is still finalizing the form of the next generation, it expects that it can navigate the FDA approval process quickly. The FDA has already confirmed that RFID is quite safe and there should be little worry about side effects (though there could be a hazard of interference for patients already using electronic medical devices such as pacemakers). https://www.diabetesdaily.com/blog/this-company-is-racing-to-create-the-worlds-first-non-invasive-cgm-718069/ XX Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes. "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management. These changes reflect our ongoing commitment to optimizing patient outcomes through informed, adaptable, and patient-centered health care practices,” said Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer. “The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes.” Notable updates to the Standards of Care in Diabetes─2024 include: New updates in managing obesity in people with diabetes, including approaches to reduce therapeutic inertia, support more personalization, and incorporate additional obesity measurements beyond body mass index (i.e., waist circumference, waist-to-hip ratio, and/or waist-to-height ratio). New screening recommendations for heart failure in people with diabetes. Updated recommendations for peripheral arterial disease (PAD) screening in people with diabetes. Guidance on screening and the use of teplizumab, approved to delay the onset of type 1 diabetes. More guidance on the use of new obesity medications, glucagon-like peptide 1 (GLP-1) agonists or dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, to reach sustained weight management goals. Updates in guidance on the diagnosis and classification of diabetes. A focus on hypoglycemia prevention and management. Emphasis on screening people with diabetes for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis at primary care and diabetes clinics. New emphasis on the evaluation and treatment of bone health and added attention to diabetes-specific risk factors for fracture. A focus on screening and management of people with diabetes and disability. Emphasis on enabling health care providers to master diabetes technology, using artificial intelligence for retinal screenings with necessary referrals, and embracing telehealth and digital tools for diabetes self-management education. New information on the possible association between COVID-19 infections and new onset of type 1 diabetes. "As the ADA's chair of professional practice committee, I'm excited to share our latest updates to advance diabetes care through new scientific insights and technological innovation, all aimed at enhancing experience for people with diabetes and health care professionals in managing this complex condition," said Nuha A. El Sayed, MD, MM Sc, the ADA's senior vice president of health care improvement. Other noteworthy changes to the 2024 Standards of Care include: Updated immunization guidance to include newly approved RSV vaccines in adults over 60 years of age with diabetes. New emphasis on cultural sensitivity in diabetes self-management education, with considerations for changing reimbursement policies. More detail and emphasis on psychosocial screening protocols to better identify diabetes distress. The importance of diabetes technology, with an emphasis on continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems. Continued emphasis on inclusion and person-centered care. “At the ADA, we are focused on improving the quality of care for anyone who lives with diabetes, prediabetes, or who is at risk of developing diabetes. The Standards of Care is critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team. These standards equip health care professionals with the gold standard in diabetes care, ensuring the highest level of service and knowledge in the field,” said Chuck Henderson, the ADA's chief executive officer. The ADA annually updates its Standards of Care through the efforts of its Professional Practice Committee (PPC). Comprising 21 global experts from diverse professional backgrounds, the PPC includes physicians, nurse practitioners, certified diabetes care and education specialists, registered dietitians, pharmacists, and methodologists. Its members hold expertise in areas like adult and pediatric endocrinology, epidemiology, public health, cardiovascular risk management, kidney disease, microvascular complications, preconception and pregnancy care, weight management, diabetes prevention, behavioral and mental health, inpatient care, and technology in diabetes management. Additionally, the committee collaborates with 19 specialized content experts. The 2024 Standards of Care has garnered endorsements from the American College of Cardiology (Section 10), the American Society of Bone and Mineral Research (Bone section in Section 4), and the Obesity Society (Section 8). Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care®. A shortened version of the guidelines, known as the Abridged Standards of Care, will be made available for primary care providers in the journal Clinical Diabetes®, along with a convenient Standards of Care app as well as a Standards of Care pocket chart. The online version will be annotated in real-time with necessary updates if new evidence or regulatory changes merit immediate incorporation through the “living” Standards of Care process. Other Standards of Care resources, including a webcast with continuing education (CE) credit and a full slide deck, can be found on the ADA's professional website, DiabetesPro®. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024 XX Join us again soon!  

Dive into the latest podcast featuring Sahil Adeem in conversation with Dr. Waseem, where they explore crucial topics:1. Muslim Masculinity: Gain insights into the discussion about Muslim masculinity, exploring perspectives and challenges in today's world.2. Engineer Muhammad Ali Mirza: Explore the insights and perspectives shared about Engineer Muhammad Ali Mirza, delving into his thoughts and contributions.3. Palestine-Israel Conflict: Join the conversation on the ongoing Palestine-Israel conflict, examining the complexities and implications of this longstanding issue.4. Boycott of Israel Products: Delve into the discourse surrounding the boycott of Israel products, exploring the rationale and impact of this movement. Hosted on Acast. See acast.com/privacy for more information.

Welcome to this week's episode of The Football Letter Podcast as we close out the regular season with another great episode.  First (0:56), we talk with Director of the Penn State All-Sports Museum, Lew Lazarow, about the museum's new photomosaic mural honoring Franco Harris, Franco's legacy at Penn State, the mission of the museum, its other featured exhibits, and more. Follow the All-Sports Museum on Facebook and X. -------------------------------------------------------------------------------------------------------------Then (20:50) , we're joined by Jeremy O'Mard, President of our African-American Alumni Organization of D.C. Alumni Interest Group. Jeremy provided an overview of the African-American Alumni Organizations (AAAOs), how the D.C. AAAO brings Penn Staters together for football watch parties, playing a role in strengthening the alumni network, his passion for giving back, and other marquee events/activities hosted by the AAAOs. Learn more about our African-American Alumni Organizations. ------------------------------------------------------------------------------------------------------------- Learn more about the Penn State Alumni Association: alumni.psu.edu. Follow the Penn State Alumni Association on:FacebookX (Twitter)InstagramLinkedIn

Adam, Chris and Marty return for the tenth(!) season of Free Ira Brown with your complete player preview for the 23-24 Gonzaga basketball season. There are a lot new faces, and some big shoes to fill, but as Mard will tell you, through song, we believe in a coach called Few. All that and our Halloween movie picks on this episode of Free Ira Brown: THE Gonzaga Hoops Podcast. @freeirabrown Freeirabrownpod on Instagram

Created by - Creative Benchers | Saade Aala Radio - A Creative Benchers Property Writers & Hosts - Harshdeep Singh, Sarabjeet Singh, Sandeep Singh D.o.P - Harjinder Singh | Sound by - Creative Benchers Edited by - Sandeep Singh | VFX - Harshdeep Singh Managed by - Creative Benchers (www.creativebenchers.com) Created by - Creative Benchers | Saade Aala Radio - A Creative Benchers Property Writers & Hosts - Harshdeep Singh, Sarabjeet Singh, Sandeep Singh D.o.P - Harjinder Singh | Sound by - Creative Benchers Edited by - Sandeep Singh | VFX - Harshdeep Singh Managed by - Creative Benchers (www.creativebenchers.com) ⁠⁠YouTube⁠⁠ ⁠⁠Facebook⁠⁠ ⁠⁠Instagram⁠⁠ ⁠⁠LinkedIn⁠⁠ ⁠⁠Twitter ⁠⁠ Hosts ⁠⁠Harshdeep Singh⁠⁠ ⁠⁠Sarabjeet Singh⁠⁠ ⁠⁠Sandeep Singh⁠⁠ ⁠⁠Support the show⁠⁠ ⁠⁠Want to promote your business?⁠⁠ CREATIVE BENCHERS A Content Based Marketing Agency Contact - hello@creativebenchers.com Saade Aala Radio -  A Creative Benchers Property

Original Air Date: 6/15/2018 The high toll Puerto Rico is paying, in both money and lives, for the triple disasters of colonialism, Hurricane Maria and disaster capitalism Be part of the show! Leave us a message or text at 202-999-3991 or email Jay@BestOfTheLeft.com BestOfTheLeft.com/Support (Members Get Bonus Clips and Shows + No Ads!) Join our Discord community! SHOW NOTES Ch. 1: Deadlier than Katrina & 9/11 Hurricane Maria Killed 4,645 in Puerto Rico, 70 Times Official Toll - @DemocracyNow - Air Date 05-30-18 Ch. 2: Colonialism during hurricane season - On the Media - 6-6-18 Ch. 3: Elizabeth Yeampierre on Puerto Rican colonialism and disaster capitalism - Infinite Earth Radio - Air Date 2-22-18 Ch. 4: The Battle for Paradise: Naomi Klein on Disaster Capitalism & the Fight for Puerto Rico's Future - @DemocracyNow - Air Date 03-21-18 Ch. 5: Naomi Klein on Puerto Rico and Disaster Capitalism - Touré Show - Air Date 4-25-18 Ch. 9: Final comments on the lessons of Mister Rogers that we could use right now   TAKE ACTION Get involved with/support Mutual Aid Disaster Relief MARD Skillshare Trainings (Links for request forms are at the bottom of the blog post) Read more about MARD ongoing work in Puerto Rico FOR FURTHER READING/SHARING FEMA Blamed Delays In Puerto Rico On Maria; Agency Records Tell Another Story (NPR/Frontline) About a quarter of Puerto Rico's schools are shutting down. Here's a look inside one. (Vox) "Justice was served": Judge halts school closures in Puerto Rico (CBS) New bill pushes for commission to investigate federal response to Puerto Rico hurricanes (NBC) At Issue In Florida Senate Campaign: Who's Fighting For Puerto Rico? (NPR) Hurricane Maria Casts Shadow Over Puerto Rican Parade (NY Times) Puerto Rico's Push For Food Independence Intertwined With Statehood Debate (NPR) The Shame in Puerto Rico (NY Times) Fighting for Those Who Can No Longer Speak (SocialistWorker.org) Resisting Disaster Capitalists and Building Solidarity in Puerto Rico (Grassroots International) Written by BOTL Communications Director Amanda Hoffman    MUSIC (Blue Dot Sessions)   Produced by Jay! Tomlinson Thanks for listening! Visit us at BestOfTheLeft.com Support the show via Patreon Listen on iTunes | Stitcher | Spotify | Alexa Devices | +more Check out the BotL iOS/Android App in the App Stores! Follow at Twitter.com/BestOfTheLeft Like at Facebook.com/BestOfTheLeft Contact me directly at Jay@BestOfTheLeft.com Review the show on iTunes and Stitcher! ​ ​

Check out my Meditation app: Level SuperMind Android - https://lvl.fit/androiddownload Ios - https://lvl.fit/iosdownload Join the Level Community Here: https://linktr.ee/levelsupermindcommunity Uorfi Javed जी को Social Media पे Follow कीजिए :- Instagram : https://instagram.com/urf7i? Facebook : https://www.facebook.com/OfficialUrf7i? Twitter : https://twitter.com/uorfi_?

In this first ever CE episode, we discuss the A-Zs of continuous glucose monitors (CGMs). In specific, our learning objective for the CE are: Describe commonly available types of continuous glucose monitors (CGMs) in the US market and the features and capabilities of these devices. Summarize the evidence and guideline recommendations for use of CGMs in the management of diabetes. Identify the role of the pharmacist in the selection of CGMs and provision of education to patients and providers. Interpret the ambulatory glucose profile (CGM data output) and recommend changes in antihyperglycemic regimen for a patient. ACPE-Accredited Pharmacist CE (1.0 hrs) To obtain CE credit for a $5 fee, visit the following link: https://rfums.wufoo.com/forms/z1qzh5vf0ggr832/. Once payment is successful, you will be redirected to our CE partner (CE Impact) to complete an evaluation and to earn 1.0 hour of CE credit. CE is available for 12 months after episode publication. Key Concepts There are two main types of stand-alone personal CGMs available in the US market – real-time (rtCGM) and intermittently scanning (isCGM). [1] These CGMs vary in their features such as sensor wear time, sensor warm up time, sensor application site, reader availability, approved age for use, fingerstick calibration, non-adjunctive FDA labeling, interconnectability with other technology such as insulin pumps, and drug interactions – these variabilities can be used in decision-making when selecting an appropriate CGM for a patient. [2-7] Based on the evidence for use, both types of CGMs (real-time and intermittently scanning) are recommended in patients with Type 1 and Type 2 diabetes who are on multiple-daily insulin or continuous insulin infusion (pump), patients with Type 2 diabetes on basal insulin therapy, and as adjunct use in patients with diabetes who are pregnant. The strength of recommendations in general is stronger for real-time CGMs than for intermittently scanning CGMs. [1,11] These recommendations are supported by the evidence that CGMs can help improve glucose control, reduce risk of hypoglycemia, diabetes-related hospitalizations, and patient/caregiver satisfaction. Pharmacists play an integral role in education, on-going support, data interpretation, and resulting disease management in patients who qualify for CGM use and providers who care for patients with diabetes. [14] The ambulatory glucose profile is a standardized data output that informs understanding of glucose trends. [15] The recommended goal for most patients is to maintain a glucose range between 70-180 mg/dL with at least 70% of time spent in this range with variability coefficient of no more than 36%. [1,11,15] Supplemental Content Comparison of rtCGM and isCGM devices "Mary's" Example AGP Report (adapted from Battelino et al.) References ElSayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association. Chapter 7. Diabetes technology: Standards of medical care in diabetes - 2023. Diabetes Care. 2023;46(suppl 1):S111-S127. Dexcom G6 User Guide. Dexcom, Inc. 2020. Accessed February 20, 2023. https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Dexcom G7 User Guide. Dexcom, Inc. 2022. Accessed February 20, 2023. https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf#page=12 Guardian Connect System User Guide. Medtronic MiniMed. 2020. Accessed February 20, 2023. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian-Connect-System-User-Guide.pdf. Eversense E3 User Guide. Sensionics, Inc. 2022. Accessed February 20, 2023. https://www.eversensediabetes.com/wp-content/uploads/LBL-4002-01-001-Rev-F_Eversense-E3-User-Guide_mgdL_R1_web.pdf FreeStyle Libre 3 User's Manual. Abbott Diabetes Care Inc. 2022. Accessed February 20, 2023. https://freestyleserver.com/Payloads/IFU/2022/q2/ART44140-002_rev-A.pdf FreeStyle Libre 2 User's Manual. Abbott Diabetes Care Inc. 2020. Accessed February 20, 2023. https://freestyleserver.com/Payloads/IFU/2020/q2/ART40703-001_rev-D-Web.pdf. Products. American Diabetes Association. Accessed February 20, 2023. https://consumerguide.diabetes.org/ Wood A, O'Neal D, Furler J, Ekinci EI. Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges. Intern Med J. 2018 May;48(5):499-508. Edelman SV, Argento NB, Petty SJ, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41:2265-2274. Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: A consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22(8):1008-21. Reiterer F, Polterauer P, Schoemaker M, Schmelzeisen-Redecker G, Freckmann G, Heinemann L, Del Re L. Significance and Reliability of MARD for the Accuracy of CGM Systems. J Diabetes Sci Technol. 2017 Jan;11(1):59-67. doi: 10.1177/1932296816662047. Epub 2016 Sep 25. PMID: 27566735; PMCID: PMC5375072. Food and Drug Administration. Premarket Notification 510(k). 2022. Accessed February 25, 2023. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k. Isaacs, Diana. The pharmacist's role in continuous glucose monitoring. Pharmacy Today. 2020;26:37-54. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603.

Learn from a local Vietnamese farmer about his daily organic practices of farming and how he integrates smart technology. Organic agriculture practices in Vietnam have been steadily increasing over the past few decades. Organic farming is popular among small-scale farmers, who account for 90% of agricultural production in Vietnam (Hanh & Karantininis, 2019). Organic farming is also common in rural areas, where farmers have limited access to chemical fertilizers and pesticides. Organic farming in Vietnam is regulated by the Ministry of Agriculture and Rural Development (MARD) and the Vietnam Organic Agriculture Association (VOAA). MARD has developed a set of standards for organic farming, which include the use of organic fertilizers, crop rotation, and the prohibition of synthetic pesticides and genetically modified organisms (GMOs) (Hanh & Karantininis, 2019). Smart technologies can enhance the productivity and efficiency of organic farming in Vietnam. The use of sensors, drones, and precision agriculture can help farmers monitor soil moisture, temperature, and nutrient levels in real-time (Nguyen, Vo, & Nguyen, 2020). These technologies can help farmers optimize crop yield, reduce water consumption, and minimize the use of chemical fertilizers and pesticides. Smart technologies can also improve food safety and traceability by enabling farmers to track the production and distribution of their crops (Nguyen, Vo, & Nguyen, 2020).

After an ultimately comfortable win over the Portland Pilots in the Chiles Center (Thanks, Ju), the Zags welcome Santa Clara on Thursday, and jump in the jet to Moraga on Saturday to take on the Gaels. This is a biggie, folks. We'll break down these games and discuss the state of the conference with special guest, Will Maupin, of the The Inlander. Also, Mard shares his special feelings about St. Mary's in the only way he knows how. Support the show! patreon.com/freeirabrown Twitter: @freeirabrown Insta: @freeirabrownpod Excerpts now available on YouTube!

This week, we discuss allyship, the utility of campaigns like MARD and #HeForShe, and what it means for cis men to hold other men accountable. Respectfully Disagree is The Swaddle Team's very own podcast series, in which we get together to discuss and dissect the issues we passionately differ on.

It's in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant. This was in rats.. but they achieved glycemic control without insulin injections and without immunosuppressive drugs for four months. AdoShell Islets is an immuno-protective synthetic biomaterial that secrets insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host's immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets. These researchers are optimistic that their unique approach can be translated from one species to another. https://www.labiotech.eu/trends-news/adocia-implants-diabetes/ XX Can starting a closed loop system right away help keep kids with type 1 in the honeymoon stage longer? New study says.. probably not. The latest findings are from the Closed Loop From Onset in Type 1 Diabetes (CLOuD) trial, a multicenter, open-label, parallel-group, randomized study, published online September 7 in the New England Journal of Medicine by Charlotte K. Boughton, PhD, and colleagues. In CLOuD, 97 youths aged 10-17 years were randomized to hybrid closed-loop therapy or standard insulin therapy (control) within 21 days of type 1 diabetes diagnosis. I found this a bit confusing, in the standard insulin therapy groups, participants could switch to insulin pump therapy or use flash or continuous glucose monitoring (CGM) or approved closed-loop systems if clinically indicated. So this isn't comparing an AID system to MDI. At 12 months, there were no differences after a mixed-meal tolerance test, with levels declining in both groups and dropping further by 24 months. Interestingly, they said glycemic control didn't differ significantly between the two groups. https://www.medscape.com/viewarticle/980356 XX Moving closer to a non-invasive way to measure blood glucose. The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute. This looks to be about the size of a Libre 3 or Dexcom G7.. It's said to have smart alarms and remote monitoring capability and just sticks on the skin. The MARD is 10 point 4, which is less accurate than CGMs on the market now, but much better than any other noninvasive device to make it this far. In addition to measuring blood glucose the makers say it can measure oxygen levels, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. Pivotal clinical study later this year and then the say they'll submit for European approval. https://www.med-technews.com/news/latest-medtech-news/glucorx-and-cardiff-university-to-bring-out-non-invasive-con/ XX RESEARCHERS in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes, before children develop symptoms or need insulin. They're offering a finger stick test when children have their pre-school vaccination. Very small start, only 60 kids, but these researchers say with a recent, more accurate test to check for markers early on, they hope to find more children before DKA sets in. https://www.oxfordmail.co.uk/news/20977659.oxford-scientists-launch-study-early-markers-type-1-diabetes-children/ XX The first Randomized Controlled Trial on open source automated insulin delivery (AID) is now published in a peer-reviewed medical journal. Big news for and from the we are not waiting crowd. The CREATE Trial evaluated the efficacy and safety of an open-source system using the OpenAPS algorithm in a modified version of AndroidAPS. This study included children and adults and found that across all ages, time in range was 14 percent higher than those who used commercial hybrid closed loop systems. There's more to it, and I”ll link it up, but this study concluded that a widely used open-source AID solution, works and is safe. Congrats to Dana Lewis and all the researchers involved. https://diyps.org/2022/09/07/nejm-publishes-rct-on-open-source-automated-insulin-delivery-openaps-algorithm-in-androidaps-in-the-create-trial/ XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Medtronic is waiting for FDA clearing of the new 780G.. already approved in Europe. New study results published in The Lancet Diabetes & Endocrinology, Medtronic announced Thursday put the AID pump up against multiple daily injections plus CGM. Small study, 82 people, all with an A1C over 8. After using the 780G for six months, the group saw a reduction of 1.4 percent in their levels with a quarter of that group dropping their A1C below 7. None of the MDI group dropped to that level. Time in range saw most improvement overnight. The MiniMed 780G system has been cleared in Europe since 2020. Medtronic submitted it to the FDA for U.S. approval in the spring of 2021 but is still awaiting a decision, slowed down by the roadblocks caused by a late 2021 warning letter from the agency that called out quality control issues at the California headquarters of its diabetes business. https://www.fiercebiotech.com/medtech/medtronics-new-minimed-insulin-pump-adds-27-boost-time-range-study-finds XX Change at one of the top posts at Dexcom. Jake Leach moves from Chief Technology Officer to Chief operating officer. He's been at the company since 2004 to work on the first commercial Dexcom CGM system. He's been a frequent guest of the show and we hope that continues. https://www.businesswire.com/news/home/20220831005236/en/DexCom-Promotes-Jake-Leach-to-Chief-Operating-Officer XX Next week we're looking ahead to the New York City Marthong. Beyond Type 1 puts together a gret team each year and I'm taking to one of the runners. He's also nabbed a spot in the world series of poker – which do you think is tougher on his type 1 diabetes? This past episode is all about Omnipod 5 – a panel of people who've sued it for a few weeks now.. and the director of medical affairs to answer your questions. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's in the news! The top stories and headlines around the diabetes community this week include a new attempt to have fewer misdiagnoses of type 2 (when it's really type 1) diabetes, a new approval for Omnipod 5 down to two years old, a look at the endocrinologist shortage in the US, a milestone for Tandem and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX New effort to avoid the very common misdiagnosis of type 2 when it's actually type 1. JDRF and a a company called IQVIA are seeing if artificial intelligence can be used here. IQVIA used machine learning to look at data from individuals diagnosed with T2D and then, later, diagnosed with T1D within a specific time frame. The big problem, the company says, is that medical records are often incomplete and are compiled using different standards and formats. They call it a good starting point though. Earlier studies have shown that possibly 40-percent of adults with new onset type 1 are first misdiagnosed with type 2. https://www.jdrf.org/blog/2022/08/11/iqvia-algorithm-for-misdiagnoses/ XX New UK study about COVID, diabetes and kids.. shows there was an increase in new cases and in DKA. This was from March 2020 to February of 2021, compared to same time the previous year. This was a large study, looking back at cases across 49 sites. There was a 17% increase in new-onset diabetes from Year 1 to Year 2, mostly of type 1 diabetes. ED visits for DKA dropped by 31.9% during the pandemic year among patients with existing diabetes. There was a 43% increase in severity of new-onset disease from Year 1 to Year 2, with severe DKA increasing by 79% (P < .001) and intensive care admissions by 89% (P < .05 There were limitations to this study, the biggest is that data was only captured for those who went to the emergency room. The question of whether SARS-CoV-2 can trigger new-onset diabetes remains unanswered. https://www.medscape.com/viewarticle/979381#:~:text=There%20was%20a%2017%25%20increase,by%2079%25%20(P%20%3C%20. XX Omipod 5 is now FDA approved for kids as young as two. Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022. That makes Omnipod 5 the only AID approved for the toddler set. Tandem's Control IQ ia approved down to age 6 and Medtronic 780G down to age 7 https://www.businesswire.com/news/home/20220822005158/en/Insulet-Announces-FDA-Clearance-of-Omnipod%C2%AE-5-for-Children-Aged-Two-Years-and-Older-with-Type-1-Diabetes XX Milestone from Tandem they say that in the first month since the new mobile bolus feature was released, users have delivered more than 1 million insulin boluses. The company said in a news release that it is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems. The company added that it is now available on approximately 30 different devices. https://www.drugdeliverybusiness.com/tandem-diabetes-app-insulin-bolus-million/ XX What looks like an editorial in a publication called Stability Health caught my eye. It's all about the shortage of endocrinologists in the US. Right now there are only 8-thousand in practice across the whole country. Endocrinologists receive the lowest compensation of all internal medicine (IM) specialties — lower even than practicing general internists — and 76–89% of medical students graduate with astronomical debt. Additionally, these clinicians often make themselves available outside of their office hours. But since this time may not be billable, it is often not supported in salaried compensation. Separately (but related), in 2016, 71% of entrants to the field of endocrinology were female. Due to America's long-standing gender wage gap, this may be a contributing factor in wage stagnation. Roughly 85% of Americans with diabetes rely on a general practitioner for their care. I'll link up the column so you can take a look. https://stabilityhealth.com/endocrinologist-shortage/?fbclid=IwAR0jx-nSiOL2UccmoJ9H74SnC6l3M5CCppecGcQ2t2M_zc7U-ydOj4JxfQ4#:~:text=Today%2C%2034.2%20million%20Americans%20are,currently%20practice%20in%20the%20U.S XX Update on one of the CGM smartwatches we've been keeping an eye on.. the K-Watch Glucose CGM watch is being tested by a French Company. They had their first clinical trials last year and got results this summer. the first run had a MARD of 29-percent.. brought down to a much better 16-percent. MARD is of course Mean Absolute Relative Difference to a calibrated meter and the gold standard right now is under 10 with Dexcom and Libre's next offerings closer to 8.. so a way to go here. https://www.notebookcheck.net/Painless-K-Watch-Glucose-blood-free-CGM-smartwatch-produces-positive-first-in-human-trial-results-as-PKvitality-targets-2024-for-availability.642380.0.html XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Association of Diabetes Care and Education Specialists gave their lifetime Achievement Award to Dr. Kenneth Moritsugu, former surgeon general of the United States. Many of you may know him as the Chairman of the Board of Children with Diabetes you see him at Friends for Life and other events. He's been involved with lot of national diabetes groups and effort – he was diagnosed with LADA at age 55. He's also been a guest of this show.. so congrats Dr. Moritsugu. https://www.healio.com/news/endocrinology/20220814/a-lifetime-of-service-a-conversation-with-kenneth-moritsugu-md-mph-facpm-faade?fbclid=IwAR2DyFSAyxCqeGMpmGHAi1FG1swihxFAPe-WveCaCP6NJrcUd0rFioBedQU XX Next week we're talking back to school! The wonderful diabetes educator Anna Sabino from Finding Smiles coaching will join me to talk 504, remote monitoring, supplies and lots more. The long format episode out right now is with Patients For Affordable Drugs about the bill that passed the Senate this week. The insulin copay cap was removed, but what does it really mean for medication prices? Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Welcome back to Not A Bomb Podcast! This week, we continue our adventure into Indian cinema with 2019's coming-of-age/action/comedy - The Man Who Feels No Pain or Mard Ko Dard Nahi Hota, as it is known in India. The podcast welcomes back Josh Hurtado from Screen Anarchy to assist in the discussion and Jose also joins for all the face-kicking action. Folks, please do yourself a favor and go watch this movie. As of this recording, it can be found on Netflix under it's original title, Mard Ko Dard Nahi Hota. It's well worth your time and we guarantee it will be one of your favorite movies of the last few years. Yes, it's that good!Timestampsintro (0:50)Box Office Results and Critical Response (8:56)Behind the Camera (14:45)In Front of the Camera (27:10)The Man Who Feels No Pain Discussion (44:39)Is a Bomb? (115:25)Listener Email (118:35)Outro - Optimism by Weird Heat - (133:07)The Man Who Feels No Pain is directed by Vasan Bala and stars Abhimanyu Dassani, Radhika Madan, Gulshan Devaiah, Mahesh Manjrekar, Jimit Trivedi, Shweta Basu Prasad, Elena Kazan, Sartaaj Kakkar, and Riva Arora.If you want to leave feedback or suggest a movie bomb, please drop us a line at NotABombPod@gmail.com. Also, if you like what you hear, leave a review on Apple Podcast.Also, read Josh's review of Mard Ko Dard Nahi Hota from Screen Anarchy. Cast: Brad, Troy, Josh, Jose